Abstract 391P
Background
Lip cancer represents 1-2% of malgnancies and accounts for 23.6-30% of all oral cancers. It is more common in the lower lip, However, it may appear in the upper lip also. Squamous cell carcinoma is the most common subtype. There is limited data to evaluate racial disparites into different age groups. So this study aims to evaluate the long-term survival outcome for lip cancer in the young and adults compared to the elderly and consider racial disparities.
Methods
Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) Program. We obtained data of patients diagnosed with lip cancer from 2000-2020. The age groups have been classified into two groups according to the National Institute of Age and divided into young and adults if less than 65 years while the old age starting from 65 years.
Results
The majority were Caucasians (99279 patients) and 114 only were African Americans. The 5-year relative survival for lip cancer in the young and adults age group was 92.6%, while in the old age group was 88.9%; P>0.0001. The 5-year relative survival of African Americans in the young and adult age was 85.9% while for Caucasiasns it was 92.5%, and in African Americans elderly the 5-year relative survival was 60.4% while in Caucasian was 88.9%; P >0.0001. The 5-year relative survival for lip cancer in localized SEER stage at the young and adults age group was 95.4%, while in the old age group 92.4% And the 5-year relative survival for lip cancer in distant stage of the disease at young and adults age group was 52.1%, while in the old age group it was 27.7%. Patients treated with combined chemoradiotherapy had a 5-year relative survival of 52.3%, while those who had no systemic therapy had a 5-year relative survival of 93.2%.
Conclusions
In this study, the results highlight significant differences in the long-term survival outcomes; Caucasians are more susceptible to devolop lip cancer than African Americans. However, African Americans have lower survival rates than Caucasians. Due to the early discovery of lip cancer, the standard treatment modality is surgical resection, which explains the significantly decreased survival related to adjuvant chemo(radio)therapy. So we recommend to avoid the systemic therapy for less unfavrouble side effect.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract